<DOC>
	<DOCNO>NCT00936065</DOCNO>
	<brief_summary>To compare efficacy ETN 50mg twice weekly 12 week follow reduction maintenance dose 25mg twice weekly week 24 combination ETN 25 mg Twice Weekly plus Acitretin 10mg BID week 24 subject moderate severe psoriasis .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety Etanercept Acitretin Korean Patient With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Active , moderate severe psoriasis define follow criterion : Clinically stable , plaque psoriasis involve 10 % body surface area ( BSA ) PASI 10 . In opinion investigator , failure , intolerance , contraindication candidate following : Methotrexate ( MTX ) , cyclosporine , psoralen plus ultraviolet A radiation ( PUVA ) therapy . Negative urine pregnancy test first dose study drug female patient Evidence skin condition ( e.g. , eczema ) psoriasis would interfere evaluation effect study medication psoriasis . Any rheumatologic disease rheumatoid arthritis , psoriatic arthritis , gout , systemic lupus erythematous , systemic vasculitis , scleroderma polymyositis , associate syndrome . Prior exposure TNF inhibitor include ETN . Prior exposure efalizumab ( Raptiva® ) alefacept ( Amevive® ) also prohibit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Etanercept</keyword>
	<keyword>Acitretin</keyword>
	<keyword>Psoriasis</keyword>
</DOC>